Jiujun Zhu

522 total citations
24 papers, 370 citations indexed

About

Jiujun Zhu is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, Jiujun Zhu has authored 24 papers receiving a total of 370 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 15 papers in Cancer Research and 8 papers in Molecular Biology. Recurrent topics in Jiujun Zhu's work include Breast Cancer Treatment Studies (10 papers), HER2/EGFR in Cancer Research (7 papers) and Cancer Immunotherapy and Biomarkers (5 papers). Jiujun Zhu is often cited by papers focused on Breast Cancer Treatment Studies (10 papers), HER2/EGFR in Cancer Research (7 papers) and Cancer Immunotherapy and Biomarkers (5 papers). Jiujun Zhu collaborates with scholars based in China, United States and Switzerland. Jiujun Zhu's co-authors include Fengyan Yu, Qiang Liu, Zhenzhen Liu, Wei Wu, Wei Tang, Fengxi Su, Shicheng Su, Dechuang Jiao, Xuhui Guo and Jingyang Zhang and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Scientific Reports.

In The Last Decade

Jiujun Zhu

23 papers receiving 366 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jiujun Zhu China 10 221 218 129 45 29 24 370
Yabing Zheng China 11 233 1.1× 207 0.9× 143 1.1× 90 2.0× 17 0.6× 40 425
Eirini Biziota Greece 8 151 0.7× 147 0.7× 158 1.2× 76 1.7× 12 0.4× 18 319
Arianna Giacobbe Italy 7 385 1.7× 252 1.2× 188 1.5× 43 1.0× 14 0.5× 7 520
Dechuang Jiao China 11 115 0.5× 139 0.6× 125 1.0× 39 0.9× 17 0.6× 30 263
Qiliang Peng China 13 260 1.2× 268 1.2× 126 1.0× 93 2.1× 41 1.4× 43 466
Chunfang Hao China 11 153 0.7× 80 0.4× 108 0.8× 58 1.3× 15 0.5× 35 286
Mohammad Ahmad United States 11 237 1.1× 116 0.5× 141 1.1× 35 0.8× 9 0.3× 19 348
Huanlei Wu China 10 201 0.9× 124 0.6× 80 0.6× 86 1.9× 23 0.8× 15 319
Ana Lameirinhas Portugal 12 269 1.2× 188 0.9× 72 0.6× 54 1.2× 15 0.5× 18 386
Liwen Bao China 7 207 0.9× 88 0.4× 135 1.0× 24 0.5× 18 0.6× 17 344

Countries citing papers authored by Jiujun Zhu

Since Specialization
Citations

This map shows the geographic impact of Jiujun Zhu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jiujun Zhu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jiujun Zhu more than expected).

Fields of papers citing papers by Jiujun Zhu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jiujun Zhu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jiujun Zhu. The network helps show where Jiujun Zhu may publish in the future.

Co-authorship network of co-authors of Jiujun Zhu

This figure shows the co-authorship network connecting the top 25 collaborators of Jiujun Zhu. A scholar is included among the top collaborators of Jiujun Zhu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jiujun Zhu. Jiujun Zhu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Liu, Zhenzhen, Jianghua Qiao, Chengzheng Wang, et al.. (2025). Abstract PS3-07: SHR-A1811 as Neoadjuvant Treatment in Patients with HR-Positive, HER2-low Breast Cancer: The first-stage results from an open-label, single-arm, two-stage, phase II clinical trial. Clinical Cancer Research. 31(12_Supplement). PS3–7. 1 indexed citations
2.
3.
4.
Jiao, Dechuang, et al.. (2022). Impact of Marital Status on Prognosis of Patients With Invasive Breast Cancer: A Population-Based Study Using SEER Database. Frontiers in Oncology. 12. 913929–913929. 5 indexed citations
5.
Zhu, Jiujun, Dechuang Jiao, Chengzheng Wang, et al.. (2022). Neoadjuvant Efficacy of Three Targeted Therapy Strategies for HER2-Positive Breast Cancer Based on the Same Chemotherapy Regimen. Cancers. 14(18). 4508–4508. 7 indexed citations
6.
Zhu, Jiujun, Dechuang Jiao, Yajie Zhao, et al.. (2021). Development of a predictive model utilizing the neutrophil to lymphocyte ratio to predict neoadjuvant chemotherapy efficacy in early breast cancer patients. Scientific Reports. 11(1). 1350–1350. 12 indexed citations
7.
Zhu, Jiujun, Dechuang Jiao, Min Yan, et al.. (2021). Clinical practice guidelines for multigene assays in patients with early-stage breast cancer: Chinese Society of Breast Surgery (CSBrS) practice guidelines 2021. Chinese Medical Journal. 134(19). 2269–2271. 1 indexed citations
8.
Guo, Xuhui, Dechuang Jiao, Jiujun Zhu, et al.. (2021). The effectiveness of axillary reverse mapping in preventing breast cancer-related lymphedema: a meta-analysis based on randomized controlled trials. Gland Surgery. 10(4). 1447–1459. 9 indexed citations
9.
Zhao, Yajie, et al.. (2021). Essential Amino Acid Metabolism-Related Molecular Classification in Triple-Negative Breast Cancer. Epigenomics. 13(16). 1247–1268. 5 indexed citations
10.
Zhao, Xin, Xuhui Guo, Dechuang Jiao, et al.. (2021). Analysis of the expression profile of serum exosomal lncRNA in breast cancer patients. Annals of Translational Medicine. 9(17). 1382–1382. 14 indexed citations
11.
Jiao, Dechuang, Jiujun Zhu, Qin Li, et al.. (2021). Clinical practice guidelines for modified radical mastectomy of breast cancer: Chinese Society of Breast Surgery (CSBrs) practice guidelines 2021. Chinese Medical Journal. 134(8). 895–897. 5 indexed citations
12.
Jiao, Dechuang, Jingyang Zhang, Jiujun Zhu, et al.. (2021). Comparison of survival in non-metastatic inflammatory and other T4 breast cancers: a SEER population-based analysis. BMC Cancer. 21(1). 138–138. 6 indexed citations
13.
Zhu, Jiujun, Chongjian Wang, Xianfu Sun, et al.. (2020). 224P Neoadjuvant pyrotinib plus trastuzumab, docetaxel, and carboplatin in patients with HER2-positive early breast cancer: A single-group, multicenter, phase II study. Annals of Oncology. 31. S331–S331. 4 indexed citations
14.
Jiao, Dechuang, Jingyang Zhang, Ping Chen, et al.. (2020). HN1L promotes migration and invasion of breast cancer by up‐regulating the expression of HMGB1. Journal of Cellular and Molecular Medicine. 25(1). 397–410. 24 indexed citations
15.
Yan, Hui, Hui Xiao, Jiujun Zhu, Jingyang Zhang, & Zhenzhen Liu. (2020). <p>Association Between the HER2 Protein Expression Level and the Efficacy of Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer</p>. Cancer Management and Research. Volume 12. 12715–12722. 8 indexed citations
16.
Liu, Shaoqing, Jingyang Zhang, Jiujun Zhu, Dechuang Jiao, & Zhenzhen Liu. (2020). Prognostic values of EDNRB in triple‑negative breast cancer. Oncology Letters. 20(5). 1–1. 12 indexed citations
17.
Zhu, Jiujun, Dechuang Jiao, Xuhui Guo, et al.. (2019). Predictive factors and prognostic value of pathologic complete response of ipsilateral supraclavicular lymph nodes in breast cancer after neoadjuvant chemotherapy. Annals of Translational Medicine. 7(22). 666–666. 11 indexed citations
18.
19.
Liu, Yujie, Haiyan Li, Juan Feng, et al.. (2013). Lin28 Induces Epithelial-to-Mesenchymal Transition and Stemness via Downregulation of Let-7a in Breast Cancer Cells. PLoS ONE. 8(12). e83083–e83083. 76 indexed citations
20.
Tang, Wei, Jiujun Zhu, Shicheng Su, et al.. (2012). MiR-27 as a Prognostic Marker for Breast Cancer Progression and Patient Survival. PLoS ONE. 7(12). e51702–e51702. 114 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yabing Zheng Breakdown of academic impact, for papers by Eirini Biziota Breakdown of academic impact, for papers by Arianna Giacobbe Breakdown of academic impact, for papers by Dechuang Jiao Breakdown of academic impact, for papers by Qiliang Peng Breakdown of academic impact, for papers by Chunfang Hao Breakdown of academic impact, for papers by Mohammad Ahmad Breakdown of academic impact, for papers by Huanlei Wu Breakdown of academic impact, for papers by Ana Lameirinhas Breakdown of academic impact, for papers by Liwen Bao
Rankless by CCL
2026